161 related articles for article (PubMed ID: 37650886)
1. High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy.
Visentini M; Pica A; D'Ippolito G; Sculco E; La Gualana F; Gragnani L; Miglionico M; Mazzaro C; Fiorilli M; Basili S; Martelli M; Di Rocco A; Casato M; Gentile G; Pulsoni A
Ann Hematol; 2023 Dec; 102(12):3457-3463. PubMed ID: 37650886
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.
Deng L; Song Y; Young KH; Hu S; Ding N; Song W; Li X; Shi Y; Huang H; Liu W; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Zhang C; Sun Y; Zhu J
Oncotarget; 2015 Sep; 6(28):25061-73. PubMed ID: 26314957
[TBL] [Abstract][Full Text] [Related]
3. HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy.
Shui LP; Zhu Y; Duan XQ; Chen YT; Yang L; Tang XQ; Zhang HB; Xiao Q; Wang L; Liu L; Luo XH
J Med Virol; 2023 Feb; 95(2):e28549. PubMed ID: 36734081
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
5. Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma.
Zhou X; Pan H; Yang P; Ye P; Cao H; Zhou H
BMC Cancer; 2019 May; 19(1):477. PubMed ID: 31113483
[TBL] [Abstract][Full Text] [Related]
6. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
9. Markers of hepatitis B infection in Tari District, Southern Highlands Province, Papua New Guinea.
Sanders RC; Lewis D; Dyke T; Alpers MP
P N G Med J; 1992 Sep; 35(3):197-201. PubMed ID: 1296422
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma.
Chen MH; Hsiao LT; Chiou TJ; Liu JH; Gau JP; Teng HW; Wang WS; Chao TC; Yen CC; Chen PM
Ann Hematol; 2008 Jun; 87(6):475-80. PubMed ID: 18327583
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients.
Attia KA; Eholié S; Messou E; Danel C; Polneau S; Chenal H; Toni T; Mbamy M; Seyler C; Wakasugi N; N'dri-Yoman T; Anglaret X
World J Hepatol; 2012 Jul; 4(7):218-23. PubMed ID: 22855697
[TBL] [Abstract][Full Text] [Related]
12. Serological hepatitis B virus (HBV) activity in patients with HBV infection and B-cell non-Hodgkin's lymphoma.
Zhou X; Wuchter P; Egerer G; Kriegsmann M; Kommoss FKF; Witzens-Harig M; Kriegsmann K
Eur J Haematol; 2020 May; 104(5):469-475. PubMed ID: 31961011
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus (HBV) serological patterns among the HBsAg negative hospital attendees screened for immunization.
Kafeero HM; Ndagire D; Ocama P; Kato CD; Wampande E; Walusansa A; Kajumbula H; Kateete D; Sendagire H
Sci Rep; 2022 May; 12(1):7425. PubMed ID: 35523938
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan.
Fwu CW; Chien YC; You SL; Nelson KE; Kirk GD; Kuo HS; Feinleib M; Chen CJ
Hepatology; 2011 Apr; 53(4):1217-25. PubMed ID: 21480326
[TBL] [Abstract][Full Text] [Related]
16. Cango Lyec (Healing the Elephant): Chronic Hepatitis B Virus among post-conflict affected populations living in mid-Northern Uganda.
Malamba SS; Muyinda H; Ogwang DM; Katamba A; Zamar DS; Jongbloed K; Sewankambo NK; Schechter MT; Spittal PM
PLoS One; 2021; 16(5):e0251573. PubMed ID: 34043637
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus seroprevalence in patients with diffuse large B cell lymphoma and Hodgkin's lymphoma.
Mert D; Merdin A; Ceken S; Dal MS; Ertek M; Altuntas F
J Cancer Res Ther; 2021; 17(4):951-955. PubMed ID: 34528547
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
19. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.
Ni Y; Gao L; Lu Y; Ye S; Zhou L; Qian W; Liang A; Li P
Front Immunol; 2022; 13():982346. PubMed ID: 36119029
[TBL] [Abstract][Full Text] [Related]
20. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
